


## The *digene* HPV Test

### The *digene*® HPV Test with Pap: Because the Pap is not enough.\*

- The sensitivity of a Pap for cervical dysplasia or cancer ranges from 55% to 84%, even when image-guided liquid-based cytology is used (2,3,4,5,6).



**Figure 1.** Co-testing using the *digene* HPV Test along with any Pap achieves close to 100% sensitivity (3,4,6).

The standard of care in cervical cancer screening has changed.  
What has NOT changed is your right to decide how often to screen your patients.

### The *digene* HPV Test: Easier than you think.

#### Ordering:

Check the box for the *digene* HPV Test with the Pap for all women 30 and older.

- Order what many of your colleagues already recognize as the state-of-the-art cervical cancer prevention solution.

#### Implementing:

Take advantage of helpful implementation tools.

- The QIAGEN Hotline answers questions about specific payers or patient benefits: 1-866-895-1478.

No other HPV test is more widely used, trusted and clinically validated.

Join your colleagues across the country by ordering the *digene* HPV Test today.

\* For women 30 years and older

# The *digene* HPV Test: FDA-approved, covered & endorsed.

## Approved:

---

The *digene* HPV Test is the **ONLY** FDA-approved HPV test for adjunctive primary screening for women 30 and older.

- The *digene* HPV Test has been validated in more than 300 peer-reviewed scientific studies (7).

## Covered:

---

Widespread reimbursement has enabled more than 13,000 clinicians to switch to co-testing (1).

- The *digene* HPV Test is covered by all major payers,\* comparable to the coverage for cytology.

## Endorsed:

---

### Professional organizations you trust support the use of the *digene* HPV Test:

American College of Obstetricians and Gynecologists

American Cancer Society

American Society for Colposcopy and Cervical Pathology

National Association of Nurse Practitioners in Women's Health

American Medical Women's Association

Association of Reproductive Health Professionals



(1) QIAGEN customer database

(2) Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, Human Papillomavirus DNA versus Pananicolau Screening

(3) Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Focialdi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. *J Natl Cancer Inst.* 98(11):765-74 (2006)

(4) Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. *Br J Cancer* 84(12):1616-23 (2001)

(5) Biscotti CV, Dawson AE, Dziura B, Galup L, Darragh T, Rahemtulla A, Wills-Frank L. Assisted primary screening using the automated ThinPrep Imaging System. *Am J Clin Pathol.* 123(2):281-7 (2005)

(6) Cytoc Package Insert: ThinPrep® Imaging System, Table 2.

(7) PubMed database. Available at: <http://www.ncbi.nlm.nih.gov/sites/entrez> . Accessed September 4, 2008

\*As with other tests, payment is based on a woman's benefit plan.

Trademarks: QIAGEN®, *digene*® (QIAGEN Group).

01/2009 © 2009 QIAGEN, all rights reserved.

[www.qiagen.com](http://www.qiagen.com)

USA ■ 800-426-8157

 Sonora Quest  
Laboratories  
A Subsidiary of Laboratory Sciences of Arizona

 QIAGEN